18/06/2026 US FDA accepts Roche’s sBLA for subcutaneous Lunsumio + Polivy in relapsed/refractory LBCL US FDA accepts Roche’s sBLA for subcutaneous Lunsumio + Polivy in relapsed/refractory LBCL (Ref) The US FDA has accepted Roche’s supplemental Biologics License Application (sBLA) for subcutaneous Lunsumio VELO (mosunetuzumab; CD20xCD3 T-cell engaging bispecific antibody) + Polivy (polatuzumab vedotin; CD79b targeting antibody-drug conjugate) in adults with relapsed/refractory

17/06/2026 Avenacy Launches Bortezomib for Injection in the U.S., Marking Its 28th Product Since Inception Avenacy Launches Bortezomib for Injection in the U.S., Marking Its 28th Product Since Inception (Ref) Avenacy has officially launched Bortezomib for Injection in the US, a generic equivalent of VELCADE® indicated for adults with multiple myeloma and mantle cell lymphoma The product is available as a 3.5 mg single-dose vial and features Avenacy's differentiated packaging

16/06/2026 US FDA grants Fast Track to givastomig, in first‑line HER2‑negative metastatic gastric cancer US FDA grants Fast Track to givastomig, in first‑line HER2‑negative metastatic gastric cancer (Ref) ABL Bio & NovaBridge's givastomig, a CLDN18.2 x 4-1BB bispecific antibody, received Fast Track status in combination with nivolumab and chemotherapy for first-line HER2-negative advanced/metastatic gastroesophageal adenocarcinomas that are CLDN18.2 and PD-L1 positive Clinica

15/06/2026 Midstage Pancreatic Cancer Study Fails to Meet Primary Endpoint but Will Advance to Phase 3 FDA accepts ozekibart BLA, setting April 2027 PDUFA for conventional Chondrosarcoma Halia Therapeutics Secures FDA Fast Track Designation for Ofirnoflast in Lower-Risk MDS Menarini Group's Phase 3 SENTRY trial met its first co-primary endpoint, with the selinexor + ruxolitinib combination achieving significant improvement in spleen volume reduction (SVR35) vs ruxolitinib alo

14/06/2026 Eli Lilly's Jaypirca Cuts Disease Progression Risk by 45% in Previously Treated CLL/SLL Eli Lilly's Jaypirca Cuts Disease Progression Risk by 45% in Previously Treated CLL/SLL (Ref) Eli Lilly announced positive Phase 3 BRUIN CLL-322 results for Jaypirca (pirtobrutinib) combined with venetoclax and rituximab in relapsed/refractory CLL/SLL, meeting its primary endpoint with a statistically significant 45% reduction in disease progression or death compared to venetocl

12/06/2026 Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC AbbVie's Venetoclax Shows Sustained 9-Year Efficacy in First-Line CLL at EHA 2026 Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC (Ref) The Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in relapsed/second-line metastatic small cell lung cancer (SCLC), did not meet its primary endpoint of overall survival (OS) fo